Genentech has reported that third quarter US net sales for Tarceva were approximately $101 million, a 1% increase over the same quarter of the last year. OSI stated that the reported US net sales reflect an approximate $13 million reserve adjustment due to unusually high product returns related to expiring inventory returned to Genentech.
US gross sales for Tarceva for the Q3 of 2007 were up 12% over the same quarter last year, primarily related to price increases, while unit volume has remained approximately stable. Despite the impact of the reserve adjustment on US sales over the last two quarters, with the continued growth of global sales, the company reaffirmed 2007 worldwide guidance for Tarceva net sales of $855 to $860 million.
Tarceva is OSI’s flagship product and the only EGFR inhibitor to have demonstrated the ability to improve survival in both non-small cell lung cancer and pancreatic cancer patients in certain settings.